Status:
COMPLETED
Efficacy of Probiotics (LiveSpo Navax) in Preventing Respiratory Diseases in Children
Lead Sponsor:
Anabio R&D
Collaborating Sponsors:
Hanoi Medical University
Conditions:
Respiratory Disease
Respiratory Infections in Children
Eligibility:
All Genders
2-5 years
Phase:
NA
Brief Summary
Acute respiratory infections are common diseases worldwide with the highest incidence and mortality rates, especially among children. Currently, the prevention of acute respiratory infections in child...
Detailed Description
Acute respiratory infections are common diseases worldwide with the highest incidence and mortality rates, especially among children. Vietnam is one of the 15 countries with the highest pneumonia rate...
Eligibility Criteria
Inclusion
- Children (male/female) aged from 2 to 5 years, currently attending a preschool.
- Parents of the pediatric agree to participate in the study, explain, and sign the research consent form.
Exclusion
- Children with a history of nasal reconstructive surgery, nasal ulcers, or nasal polyps.
- Children with a history of congenital immunodeficiency or infectious diseases (e.g., HIV).
- Children who regularly use products that may affect the research outcomes (e.g., immunosuppressive/immunostimulant drugs, pain relievers/anti-inflammatory drugs, anti-cough/expectorant drugs, antihistamines, or other probiotics) within 4 weeks before the start of the study.
- Children with co-morbidities that affect cognition and perception.
Key Trial Info
Start Date :
January 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 23 2024
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06148194
Start Date
January 2 2024
End Date
October 23 2024
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Son Tay Province, Hanoi
Hanoi, Vietnam, 10000